FDA 510(k) FDA class 2 Substantially Equivalent 🇺🇸 United States

0.9 % Sodium Chloride Injection, USP, BD PosiFlush™ SP Syringe

K Number: K250884 · Decision Dec 2, 2025
Classifications
1
FEI Numbers
51
Registration Numbers
51
Same Product Code
39
Applicant Total
134
Review Days
253

Basic Information

Device Name
0.9 % Sodium Chloride Injection, USP, BD PosiFlush™ SP Syringe
K Number
K250884
Device Class
FDA class 2
Clearance Type
Traditional
Regulation Number
880.5200
Medical Specialty
General Hospital
Decision
Substantially Equivalent
Statement or Summary
Summary
Applicant
Becton, Dickinson and Company
Date Received
March 24, 2025
Decision Date
December 2, 2025
Product Code
NGT
Advisory Committee
General Hospital
Review Advisory Committee
HO
Third Party
N

Classifications

This FDA 510(k) entry is associated with 1 FDA classification via its product code.

Product Code Device Name
NGT Saline, Vascular Access Flush

Similar 510(k) Clearances

Other 510(k) clearances with the same product code (NGT), ordered by most recent decision date.

View all

Other Clearances by Becton, Dickinson and Company

K Number Device Name
K260128 BD Preset™ and BD A-Line™ Arterial Blood Collection Syringes
K252506 BD Vacutainer® Safety-Lok™ Blood Collection Set; BD Vacutainer® Safety-Lok™ Blood Collection Set with Pre-Attached Holder
K252378 BD® MiniDraw™ Capillary Blood Collection System with BD® MiniDraw™ SST™ Capillary Blood Collection Tube
K260184 Onclarity™ Self-Collection Kit
K252040 BD Vacutainer® Plasma Separator Tubes (PST™), BD Vacutainer® Sodium Heparin Blood Collection Tubes
K250358 BD Enteric Bacterial Panel for BD COR System, BD Enteric Bacterial Panel plus for BD COR System, and Enteric Bacterial Panel Diluent for BD COR System
K250059 BD PhaSeal™ Optima Connecting Set (C83-O); BD PhaSeal™ Optima Spike Set (C180-O)
K251713 BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL)
K251350 BD Plastipak™ Syringe
K243207 BD Vacutainer® Eclipse™ Blood Collection Needle
Search all 134 clearances from Becton, Dickinson and Company →